PPHM Bavituximab is a chimeric monoclonal antibodies which binds to a PPHM exclusive site on malignant/oxidatively stressed cell surfaces. The private landing site that beckons Bavituximab and its lethal passengers is a "flipped" membrane lipoprotein, phosphatidylserine (-PS), and the downstream effects of occupying that particular -PS cellular binding sites is that the mere act of binding the landing sites invokes the correct body response to the presence of a "worm" within the membrane perimeter. In short, Bavituximab calls in the "anti-growth" crowd for a cycle of, uh, cleansing of undesirable degenerates. Bavituximab has, in both lower animal and advanced FDA patient-trials, slowed, stopped, reversed, and apparently immunized subsets of patients against recurrence of certain solid tumors (and probably hematogenous malignancies also). Bavituximab's capability of carrying imaging agents and cytotoxic agents directly to tumor has been clearly established. The role of Bavituximab in such systemic disease as Altzheimer's and autoimmunity, and antiPS syndrome is being studied and the anti-phospholipid therapeutic program is slowly struggling toward the marketplace. Meanwhile, Big Pharma has once again revealed the extent to which we are captive to hedge fund, arbitrage, swaps, futures, shorts and other marketing frauds. And PPHM is set back a full year by an obvious outside error or fraud. Too bad those involved did not apply themselves to pure science. Wall street denizens are clearly evolving and prospering more rapidly than, say bench scientists, or medical practitioners. Cheers for the weekend, all. We'll see how long the genius of our founder, Dr. Philip Thorpe, holds out against patent jumpers and laboratory technology pirates.
